Triple Negative Breast Cancer: Molecular Classification, Prognostic Markers and Targeted Therapies

Abstract

Context: Despite the improvements that have been made in treatment of breast cancer, upper-limb lymphedema is still an unsolved problem in the treatment of women with breast cancer. Upper extremity lymphedema may accompany with decreased in shoulder range of motion and strength, and also pain. Nowadays, exercise training acts as a treatment method to control lymphedema in breast cancer survivors. Therefore, this study reviews the results of the applied studies in this field to survey the influences of exercise training on lymphedema and to determine its related symptoms in women with breast cancer. Data Sources: Literature investigation was conducted on August 1st, 2016 using PUBMED, MEDLINE, CINAHL, and Google Scholar databases. Study Selection: Randomized and nonrandomized controlled trials published in English were included. Twelve trails met inclusion criteria. Data Extraction: Data were extracted in a standardized manner into the predefined table. Then, quality of the studies was evaluated using the guide to community preventive services tool. Conclusions: It can be seen that a few studies have examined the effect of exercise training on lymphedema to conduct a review study. So, lymphedema continues to be a problem for breast cancer survivors. According to most studies, aerobic, resistance and stretching training programs had no influence on the volume and circumference of arm in lymphedema cancer patients, but the training had a noticeable influence on quality of life

BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile

“…Triple negative breast cancer (TNBC), accounts for 15% to 20% of all breast cancers, is defined by low or lack of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression. TNBC is characterized by aggressive clinical behavior, poor prognosis in the first 5 years and the lack of common therapeutic targets for effective therapy compared to other types of breast cancer …”